Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib plus venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib plus venetoclax in CLL
CANCER RESEARCH（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要